Polarean receives FDA clearance supporting collaboration with Philips
The Polarean XENOVIEW Chest Coil is a flexible, single channel, transmit-receive RF coil tuned to image 129Xe nuclei while a patient is positioned inside an MRI scanner.
Christopher von Jako, CEO of Polarean, said: "Polarean continues to develop and launch new devices and accessories that empower sites to perform modern respiratory imaging, enabling as many clinicians as possible to use our technology for their patients. This FDA clearance also further supports our recently announced collaboration with Philips, by expanding our product line to be compatible with their advanced MRI systems."
View from Vox
The news today builds on the announcement in June that Philips' MR 7700 MRI scanner was to be combined with XENOVIEW technology, showcasing the capability to enhance pulmonary imaging. Polarean's collaboration with a major industry player marks a significant milestone, demonstrating the wide applicability of Polarean's technology and positioning the company for increased visibility and recognition within the medical imaging market.
Polarean’s XENOVIEW 3.0T Chest Coil was cleared by the FDA in December 2022.
It’s estimated that almost 550 million people worldwide are living with chronic lung disease, demonstrating the huge demand for medical imaging to aid in early diagnosis. Providing an enhanced picture of the lungs may help a variety of patients suffering from lung diseases, which can include idiopathic pulmonary fibrosis, COPD, pulmonary hypertension, radiation therapy, cystic fibrosis and asthma.
Polarean remains well-funded, with $16.5m in the bank at the end of 2022, positioning it well to continue advancing XENOVIEW across various stages of commercialisation in the US and beyond.
Follow Polarean for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.